ScholarIQanswers from OpenAlex & ORCID
Michael Kneba
ResearcherPublications, citations & collaboration network
Michael Kneba is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Michael Kneba have?
ScholarIQindexed works
Michael Kneba has 505 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Michael Kneba have?
ScholarIQcitation count
Michael Kneba has 48,173 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Michael Kneba?
ScholarIQh-index
Michael Kneba has an h-index of 94 in OpenAlex.
What is the i10-index of Michael Kneba?
ScholarIQi10-index
Michael Kneba has an i10-index of 247 in OpenAlex.
What is the OpenAlex record for Michael Kneba?
ScholarIQopenalex
The OpenAlex for Michael Kneba is on the source record.
What are the most-cited papers on Michael Kneba?
ScholarIQmost cited works
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Michael Hallek, Kirsten Fischer, Guenter Fingerle-Rowson, AM Fink, R. Busch, Jiřı́ Mayer, M. Hensel, Georg Hopfinger, G Hess, Ulrich von Grünhagen, Michèle Bergmann, J. Catalano, Pier Luigi Zinzani, Federico Caligaris‐Cappio, JF Seymour, A Berrébi, Ulrich Jäger, Bruno Cazin, Marek Trněný, Anne Westermann, C-M Wendtner, BF Eichhorst, Peter Staib, Andreas Bühler, Dirk Winkler, Thorsten Zenz, Sebastian Böttcher, Matthias Ritgen, Myriam Mendila, Michael Kneba, Hartmut Döhner, S. Stilgenbauer
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, Thorsten Zenz, Marianna Rossi, Konstanze Döhner, Andreas Bühler, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Dirk Winkler, Eugen Tausch, Patrick Hoth, Jennifer Edelmann, Daniel Mertens, Lars Bullinger, Manuela Bergmann, Sabrina Kless, Silja Mack, Ulrich Jäger, Nancy Patten, Lin Wu, Michael Wenger, Günter Fingerle‐Rowson, Peter Lichter, Mario Cazzola, Clemens‐Martin Wendtner, Anna Maria Fink, Kirsten Fischer, Raymonde Busch, Michael Hallek, Hartmut Döhner
Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
Kirsten Fischer, Paula Cramer, Raymonde Busch, Sebastian Böttcher, Jasmin Bahlo, Jöerg Schubert, Karl Heinz Pflüger, Silke Schott, Valentin Goede, Susanne Isfort, Julia von Tresckow, Anna‐Maria Fink, Andreas Bühler, Dirk Winkler, Karl‐Anton Kreuzer, Peter Staib, Matthias Ritgen, Michael Kneba, Hartmut Döhner, Barbara Eichhorst, Michael Hallek, Stephan Stilgenbauer, Clemens‐Martin Wendtner
Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
Kirsten Fischer, Paula Cramer, Raymonde Busch, Stephan Stilgenbauer, Jasmin Bahlo, Carmen D. Schweighofer, Sebastian Böttcher, Peter Staib, Michael Kiehl, Michael J. Eckart, Gabriele Kranz, Valentin Goede, Thomas Elter, Andreas Bühler, Dirk Winkler, Michael Kneba, Hartmut Döhner, Barbara Eichhorst, Michael Hallek, Clemens‐Martin Wendtner
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
Peter Dreger, Hartmut Döhner, Matthias Ritgen, Sebastian Böttcher, Raymonde Busch, Sascha Dietrich, Donald Bunjes, Sandra Cohen, Jörg Schubert, Ute Hegenbart, Dietrich W. Beelen, Matthias Zeis, Michael Stadler, Justin Hasenkamp, Lutz Uharek, Christof Scheid, Andreas Humpe, Thorsten Zenz, Dirk Winkler, Michael Hallek, Michael Kneba, Norbert Schmitz, Stephan Stilgenbauer, for the German CLL Study Group